Baird Financial Group Inc. Sells 406,942 Shares of Pfizer Inc. $PFE

Baird Financial Group Inc. trimmed its stake in Pfizer Inc. (NYSE:PFE) by 14.5% in the 2nd quarter, Holdings Channel.com reports. The firm owned 2,394,629 shares of the biopharmaceutical company’s stock after selling 406,942 shares during the period. Baird Financial Group Inc.’s holdings in Pfizer were worth $58,046,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of PFE. GKV Capital Management Co. Inc. bought a new stake in Pfizer in the first quarter worth $27,000. Curio Wealth LLC raised its stake in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares during the period. Bayforest Capital Ltd bought a new stake in shares of Pfizer in the 1st quarter worth about $28,000. Harbor Asset Planning Inc. purchased a new position in shares of Pfizer during the 2nd quarter worth about $29,000. Finally, Evelyn Partners Asset Management Ltd bought a new position in Pfizer during the 2nd quarter valued at about $33,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the subject of several analyst reports. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a report on Wednesday, November 5th. Morgan Stanley dropped their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Scotiabank initiated coverage on Pfizer in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price objective on the stock. Finally, Sanford C. Bernstein reiterated a “market perform” rating and set a $30.00 target price on shares of Pfizer in a research report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $28.39.

Pfizer Price Performance

NYSE PFE opened at $25.69 on Friday. The company has a market cap of $146.04 billion, a PE ratio of 14.93 and a beta of 0.46. The firm’s 50 day moving average price is $25.12 and its 200-day moving average price is $24.65. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 7th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.